**Core Concept:** Triple-negative breast cancer (TNBC) is a subset of breast cancer with negative expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These negative receptors are crucial in determining treatment options and prognosis.

**Why the Correct Answer is Right:** Triple-negative breast cancer refers to a specific subtype of breast cancer that lacks expression of estrogen receptors, progesterone receptors, and HER2. These negative receptors make TNBC challenging to treat with standard endocrine therapies and HER2-targeted agents. The absence of these targets also correlates with a worse prognosis and higher risk of recurrence.

**Why Each Wrong Option is Incorrect:**

A. Positive ER and PR expression: This option contradicts the definition of triple-negative breast cancer by stating that the tumor has positive expression of at least one receptor.
B. HER2 overexpression: Unlike the correct answer, this option indicates HER2 overexpression, which is not part of the definition of triple-negative breast cancer.
C. Mixed receptor expression: This option implies a mixed expression of receptors, which is inconsistent with the definition of triple-negative breast cancer.
D. HER2 amplification: Similar to option B, this option describes HER2 amplification instead of negativity, which contradicts the definition of triple-negative breast cancer.

**Clinical Pearl:** Understanding the receptor status of breast cancer is crucial for selecting appropriate treatment options. Triple-negative breast cancer poses a challenge in therapy, as traditional targeted therapies are not effective. However, clinical trials are ongoing to explore new treatment strategies, including immunotherapy.

**Correct Answer:** C. Mixed receptor expression

**Why This is the Correct Answer:** The correct answer, "mixed receptor expression," refers to a breast cancer tumor that expresses both ER and PR, but not HER2. This option aligns with the definition of triple-negative breast cancer, which excludes tumors with HER2 overexpression or amplification. However, it is crucial to note that mixed receptor expression is an exception to the general definition of triple-negative breast cancer, which typically lacks expression of all three receptors (ER, PR, and HER2).